224 related articles for article (PubMed ID: 23268419)
1. [Cytokeratin immunoreactivity patterns in the diagnosis of Barrett's esophagus].
Wang R; Xie J; Shen Y; Ren T
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1820-3. PubMed ID: 23268419
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin immunoreactivity patterns in short-segment Barrett's esophagus in Japanese patients.
Yagi K; Nakamura A; Sekine A
J Gastroenterol Hepatol; 2005 Jun; 20(6):929-34. PubMed ID: 15946143
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus.
Ormsby AH; Vaezi MF; Richter JE; Goldblum JR; Rice TW; Falk GW; Gramlich TL
Gastroenterology; 2000 Sep; 119(3):683-90. PubMed ID: 10982762
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.
Shearer C; Going J; Neilson L; Mackay C; Stuart RC
Histopathology; 2005 Sep; 47(3):268-75. PubMed ID: 16115227
[TBL] [Abstract][Full Text] [Related]
5. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction.
Jovanovic I; Tzardi M; Mouzas IA; Micev M; Pesko P; Milosavljevic T; Zois M; Sganzos M; Delides G; Kanavaros P
Histol Histopathol; 2002 Apr; 17(2):445-54. PubMed ID: 11962749
[TBL] [Abstract][Full Text] [Related]
6. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
DeMeester SR; Wickramasinghe KS; Lord RV; Friedman A; Balaji NS; Chandrasoma PT; Hagen JA; Peters JH; DeMeester TR
Am J Gastroenterol; 2002 Oct; 97(10):2514-23. PubMed ID: 12385432
[TBL] [Abstract][Full Text] [Related]
8. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
Mohammed IA; Streutker CJ; Riddell RH
Mod Pathol; 2002 Jun; 15(6):611-6. PubMed ID: 12065774
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach.
Ormsby AH; Goldblum JR; Rice TW; Richter JE; Falk GW; Vaezi MF; Gramlich TL
Hum Pathol; 1999 Mar; 30(3):288-94. PubMed ID: 10088547
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens.
El-Zimaity HM; Graham DY
Am J Gastroenterol; 2001 May; 96(5):1378-82. PubMed ID: 11374671
[TBL] [Abstract][Full Text] [Related]
11. Barrett's esophagus and cardiac intestinal metaplasia: two conditions within the same spectrum.
White NM; Gabril M; Ejeckam G; Mathews M; Fardy J; Kamel F; Doré J; Yousef GM
Can J Gastroenterol; 2008 Apr; 22(4):369-75. PubMed ID: 18414711
[TBL] [Abstract][Full Text] [Related]
12. Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia.
Liu GS; Gong J; Cheng P; Zhang J; Chang Y; Qiang L
World J Gastroenterol; 2005 Oct; 11(40):6360-5. PubMed ID: 16419166
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and COX2 expressions using chromoendoscopical examination.
Çoban Ş; Örmeci N; Savaş B; Ekiz F; Ensari A; Kuzu I; Palabıyıkoğlu M
Dis Esophagus; 2013; 26(2):189-96. PubMed ID: 22591041
[TBL] [Abstract][Full Text] [Related]
14. Barrett's esophagus and intestinal metaplasia of gastric cardia: prevalence, clinical, endoscopic and histological features.
Pascarenco OD; Boeriu A; Mocan S; Pascarenco G; Drasoveanu S; Galeanu M; Dobru D
J Gastrointestin Liver Dis; 2014 Mar; 23(1):19-25. PubMed ID: 24689092
[TBL] [Abstract][Full Text] [Related]
15. Is Barrett's esophagus associated with intestinal metaplasia of the gastric cardia?
Morales TG; Bhattacharyya A; Johnson C; Sampliner RE
Am J Gastroenterol; 1997 Oct; 92(10):1818-22. PubMed ID: 9382043
[TBL] [Abstract][Full Text] [Related]
16. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia.
Weston AP; Krmpotich P; Makdisi WF; Cherian R; Dixon A; McGregor DH; Banerjee SK
Am J Gastroenterol; 1996 May; 91(5):981-6. PubMed ID: 8633592
[TBL] [Abstract][Full Text] [Related]
17. Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett's oesophagus in Korea?
Yim HJ; Lee SW; Choung RS; Kim YS; Kim JY; Lee HS; Song CW; Choi JH; Bak YT; Ryu HS; Hyun JH; Kim DS; Kim CH
Eur J Gastroenterol Hepatol; 2005 Jun; 17(6):611-6. PubMed ID: 15879722
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of cytokeratin immunoreactivity pattern for distinction of Barrett's esophagus from intestinal metaplasia of the stomach.
Iwata T; Kurita N; Nishioka M; Hidenori M; Wakatsuki S; Sano T; Shimada M
Hepatogastroenterology; 2007 Sep; 54(78):1710-2. PubMed ID: 18019700
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intestinal metaplasia in gastric cardia and Barrett's esophagus.
Miao Q; Peng YS; Cai GH; Chen XY
J Dig Dis; 2011 Aug; 12(4):272-8. PubMed ID: 21791021
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
Couvelard A; Cauvin JM; Goldfain D; Rotenberg A; Robaszkiewicz M; Fléjou JF;
Gut; 2001 Dec; 49(6):761-6. PubMed ID: 11709508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
